JP2022041802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022041802A5 JP2022041802A5 JP2020187708A JP2020187708A JP2022041802A5 JP 2022041802 A5 JP2022041802 A5 JP 2022041802A5 JP 2020187708 A JP2020187708 A JP 2020187708A JP 2020187708 A JP2020187708 A JP 2020187708A JP 2022041802 A5 JP2022041802 A5 JP 2022041802A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- weeks
- administered
- pharmaceutical composition
- pruritus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 claims 40
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 208000003251 Pruritus Diseases 0.000 claims 24
- 238000000502 dialysis Methods 0.000 claims 24
- 238000011282 treatment Methods 0.000 claims 14
- 238000011321 prophylaxis Methods 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 6
- 208000019116 sleep disease Diseases 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 230000004044 response Effects 0.000 claims 3
- 208000022925 sleep disturbance Diseases 0.000 claims 3
- 238000009121 systemic therapy Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 102100021594 Interleukin-31 receptor subunit alpha Human genes 0.000 claims 2
- 101710131691 Interleukin-31 receptor subunit alpha Proteins 0.000 claims 2
- 239000004909 Moisturizer Substances 0.000 claims 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 239000000043 antiallergic agent Substances 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 229940125715 antihistaminic agent Drugs 0.000 claims 2
- 230000009260 cross reactivity Effects 0.000 claims 2
- 238000002513 implantation Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000001333 moisturizer Effects 0.000 claims 2
- 229960000441 nalfurafine Drugs 0.000 claims 2
- XGZZHZMWIXFATA-UEZBDDGYSA-N nalfurafine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3N(C)C(=O)\C=C\C1=COC=C1)CN2CC1CC1 XGZZHZMWIXFATA-UEZBDDGYSA-N 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 230000004620 sleep latency Effects 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 206010062519 Poor quality sleep Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020187708A JP7548784B2 (ja) | 2020-09-01 | 2020-11-11 | Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2020/032987 WO2022049614A1 (ja) | 2020-09-01 | 2020-09-01 | Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
| JP2020551453A JP6799831B1 (ja) | 2020-09-01 | 2020-09-01 | Ｉｌ−３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
| JP2020187708A JP7548784B2 (ja) | 2020-09-01 | 2020-11-11 | Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551453A Division JP6799831B1 (ja) | 2020-09-01 | 2020-09-01 | Ｉｌ−３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022041802A JP2022041802A (ja) | 2022-03-11 |
| JP2022041802A5 true JP2022041802A5 (cg-RX-API-DMAC7.html) | 2023-07-26 |
| JP7548784B2 JP7548784B2 (ja) | 2024-09-10 |
Family
ID=73741045
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551453A Active JP6799831B1 (ja) | 2020-09-01 | 2020-09-01 | Ｉｌ−３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
| JP2020187708A Active JP7548784B2 (ja) | 2020-09-01 | 2020-11-11 | Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551453A Active JP6799831B1 (ja) | 2020-09-01 | 2020-09-01 | Ｉｌ−３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230391878A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4209227A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6799831B1 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102800698B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN116096411A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020466800A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3189847A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300694A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002482A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022049614A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA43918A (fr) | 2015-04-14 | 2018-12-05 | Chugai Pharmaceutical Co Ltd | Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 |
| HRP20250972T1 (hr) | 2015-04-14 | 2025-10-10 | Chugai Seiyaku Kabushiki Kaisha | Farmaceutski pripravak za prevenciju i/ili liječenje atopijskog dermatitisa koji sadrži il-31 antagonist kao djelatni sastojak |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| EP4062933A4 (en) | 2019-11-20 | 2023-12-13 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
| WO2025167991A1 (zh) * | 2024-02-07 | 2025-08-14 | 武汉人福创新药物研发中心有限公司 | 一种靶向il-31ra的抗体或其抗原结合片段及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| ATE455852T1 (de) | 1999-06-02 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Neues hämopoietin rezeptorprotein nr10 |
| ES2335861T3 (es) | 2000-09-08 | 2010-04-06 | Universitat Zurich | Grupos de proteinas repetitivas que comprenden modulos repetitivos. |
| EP1356075A4 (en) | 2000-10-16 | 2005-04-13 | Compound Therapeutics Inc | PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| JP2002338476A (ja) * | 2001-05-21 | 2002-11-27 | Health Factor Kenkyusho:Kk | 腎透析に伴う痒みの予防治療剤 |
| US7494804B2 (en) | 2002-01-18 | 2009-02-24 | Zymogenetics, Inc. | Polynucleotide encoding cytokine receptor zcytor17 multimer |
| CA2555340A1 (en) | 2004-02-12 | 2005-09-01 | Lexicon Genetics Incorporated | Gene disruptions, compositions and methods relating thereto |
| EP1671642A1 (en) | 2004-12-15 | 2006-06-21 | Universite D'angers | Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof. |
| AU2006214325B2 (en) | 2005-02-14 | 2012-04-05 | National Jewish Medical And Research Center | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| CA2594490A1 (en) | 2005-02-14 | 2006-08-24 | Zymogenetics Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| JP5065253B2 (ja) | 2005-05-06 | 2012-10-31 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１モノクローナル抗体とその使用法 |
| CN101589060A (zh) * | 2006-01-10 | 2009-11-25 | 津莫吉尼蒂克斯公司 | 使用il-31拮抗剂在神经元性组织中治疗疼痛和炎症的方法 |
| JP2009528264A (ja) | 2006-01-10 | 2009-08-06 | ザイモジェネティクス，インコーポレイティド | Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法 |
| CA2654623C (en) | 2006-06-08 | 2016-07-26 | Chugai Seiyaku Kabushiki Kaisha | An anti-nr10/il-31ra antibody for use in preventing or treating an inflammatory disease |
| PL2594586T3 (pl) | 2006-09-01 | 2015-02-27 | Zymogenetics Inc | Przeciwciała monoklonalne IL-31 i sposoby ich zastosowania |
| KR20160074019A (ko) | 2007-12-05 | 2016-06-27 | 추가이 세이야쿠 가부시키가이샤 | 항ｎｒ１０ 항체 및 그의 이용 |
| MY185647A (en) | 2007-12-05 | 2021-05-27 | Chugai Pharmaceutical Co Ltd | Therapeutic agent for pruritus |
| CA2708251C (en) | 2007-12-07 | 2016-04-12 | Zymogenetics, Inc. | Humanized antibody molecules specific for il-31 |
| JP2010210772A (ja) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| JP5650871B1 (ja) * | 2013-06-28 | 2015-01-07 | 中外製薬株式会社 | そう痒を伴う疾患に罹患した患者のｉｌ−３１アンタゴニストによる治療に対する応答を予測する方法 |
| WO2015025767A1 (ja) * | 2013-08-21 | 2015-02-26 | 久光製薬株式会社 | 貼付剤 |
| US20190135804A1 (en) * | 2017-11-03 | 2019-05-09 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Compositions and methods for the inhibition of pruritus |
| KR102156932B1 (ko) * | 2017-11-23 | 2020-09-17 | 주식회사 헬릭스미스 | 천연추출물을 포함하는 소양증의 예방 또는 치료용 조성물 |
| JP2021522241A (ja) * | 2018-04-25 | 2021-08-30 | キニクサ ファーマシューティカルズ， リミテッド | 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療 |
-
2020
- 2020-09-01 WO PCT/JP2020/032987 patent/WO2022049614A1/ja not_active Ceased
- 2020-09-01 US US18/023,246 patent/US20230391878A1/en active Pending
- 2020-09-01 IL IL300694A patent/IL300694A/en unknown
- 2020-09-01 KR KR1020217018823A patent/KR102800698B1/ko active Active
- 2020-09-01 MX MX2023002482A patent/MX2023002482A/es unknown
- 2020-09-01 EP EP20952354.7A patent/EP4209227A4/en active Pending
- 2020-09-01 CA CA3189847A patent/CA3189847A1/en active Pending
- 2020-09-01 KR KR1020207030800A patent/KR102269716B1/ko active Active
- 2020-09-01 AU AU2020466800A patent/AU2020466800A1/en active Pending
- 2020-09-01 CN CN202080103639.6A patent/CN116096411A/zh active Pending
- 2020-09-01 JP JP2020551453A patent/JP6799831B1/ja active Active
- 2020-11-11 JP JP2020187708A patent/JP7548784B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022041802A5 (cg-RX-API-DMAC7.html) | ||
| Kuriyama et al. | Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis | |
| HRP20100014T1 (hr) | Uporaba il-23 i il-17 antagonista u liječenju autoimune očne upalne bolesti | |
| TWI738648B (zh) | 含有ｉｌ－３１拮抗劑作為有效成分之異位性皮膚炎的預防用及／或治療用醫藥組合物 | |
| JP2017160178A5 (cg-RX-API-DMAC7.html) | ||
| CN116059204A (zh) | 用于治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法 | |
| JP2010509369A5 (cg-RX-API-DMAC7.html) | ||
| Khan et al. | Tramadol use in premature ejaculation: daily versus sporadic treatment | |
| US11123329B1 (en) | Use of angiotensin II type 2 receptor agonist | |
| Goodman et al. | Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy) | |
| CN111372948A (zh) | 用il-17拮抗剂治疗化脓性汗腺炎 | |
| JP7309816B2 (ja) | 結節性痒疹患者における皮膚病変およびそう痒の治療 | |
| JP2018515493A5 (cg-RX-API-DMAC7.html) | ||
| KR20220112803A (ko) | 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 | |
| JP2018534259A5 (cg-RX-API-DMAC7.html) | ||
| Saco et al. | Prurigo nodularis: Picking the right treatment. | |
| EP2844291A1 (en) | Methods for treating idiopathic pulmonary fibrosis | |
| JP2015522077A5 (cg-RX-API-DMAC7.html) | ||
| KR20180017145A (ko) | 소양증의 치료 | |
| JP2025176134A (ja) | 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ | |
| KR20230054444A (ko) | 호흡기 질환 치료에 사용하기 위한 (1r,3s)-3-((5-시아노-4-페닐티아졸-2-일)카바모일)사이클로펜탄-1-카르복시산 및 이의 유도체 | |
| Lewis et al. | Oral gold: a comparison with placebo and with intramuscular sodium aurothiomalate | |
| AU2015305430A1 (en) | Method for treating hyperhidrosis | |
| JPWO2020039256A5 (cg-RX-API-DMAC7.html) | ||
| Skoner | Montelukast in 2‐to 5‐year‐old children with asthma |